#futureoftreatment

A new ctDNA‑guided colorectal cancer trial is reshaping how recurrence risk is managed.

Patients who appear disease‑free on imaging but still show molecular traces of cancer in their blood are now being offered early‑intervention therapy. TTX‑MC138 blocks a microRNA associated with aggressive tumor behavior, aiming to eliminate residual cancer cells before they can rebuild.

Expert centers, adaptive trial platforms, and ctDNA‑based monitoring are working together to deliver faster enrollment, more precise treatment decisions, and a more personalized path forward for high‑risk patients.

Discover more on Banish Cancer Blog.